Spruce Biosciences, Inc. Common Stock
SPRB Real Time Price USDRecent trades of SPRB by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by SPRB's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Corticotropin releasing factor receptor antagonists Oct. 15, 2024
-
Patent Title: Methods and compositions for treating polycystic ovary syndrome Sep. 24, 2024
-
Patent Title: Corticotropin releasing factor receptor antagonists Jun. 11, 2024
-
Patent Title: Methods and compositions for treating polycystic ovary syndrome Jan. 02, 2024
-
Patent Title: Crystalline composition of tildacerfont and methods of use and preparation thereof Jul. 25, 2023
-
Patent Title: Corticotropin releasing factor receptor antagonists Jun. 07, 2022
-
Patent Title: Corticotropin releasing factor receptor antagonists May. 31, 2022
-
Patent Title: Corticotropin releasing factor receptor antagonists Apr. 26, 2022
-
Patent Title: Methods for treating testicular and ovarian adrenal rest tumors Apr. 19, 2022
-
Patent Title: Corticotropin releasing factor receptor antagonists May. 18, 2021
-
Patent Title: Corticotropin releasing factor receptor antagonists Dec. 01, 2020
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of SPRB in WallStreetBets Daily Discussion
Recent insights relating to SPRB
Recent picks made for SPRB stock on CNBC
ETFs with the largest estimated holdings in SPRB
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view SPRB Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.